Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Biotech Industry Analysis

UpdatedMay 28, 2026
DataAggregated Company Financials
Companies549
  • 7D1.0%
  • 3M-3.9%
  • 1Y34.2%
  • YTD2.0%

In the last week, the Biotech industry is up 1.0%, with AbbVie up 1.5%. This means that the industry has gained 34% over the past year. Earnings are forecast to grow by 25% annually.

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 28 May 2026US$1.3tUS$170.0b-US$12,287,215,245.0016.3x-105.2x7.6x
Sat, 25 Apr 2026US$1.3tUS$166.2b-US$12,110,405,958.9817.8x-108.3x7.9x
Mon, 23 Mar 2026US$1.3tUS$169.3b-US$15,183,787,576.9716.7x-82.6x7.4x
Wed, 18 Feb 2026US$1.3tUS$168.9b-US$12,920,983,375.6622.2x-103.4x7.9x
Fri, 16 Jan 2026US$1.2tUS$163.5b-US$15,150,534,323.5420.1x-81.7x7.6x
Sun, 14 Dec 2025US$1.2tUS$163.7b-US$15,628,369,300.4319x-78x7.4x
Tue, 11 Nov 2025US$1.1tUS$163.6b-US$15,778,894,049.8917.1x-71.9x6.9x
Thu, 09 Oct 2025US$1.1tUS$163.4b-US$18,204,173,729.7516.7x-62.5x7x
Sat, 06 Sep 2025US$1.1tUS$163.6b-US$18,346,651,759.6015.7x-58.4x6.5x
Mon, 04 Aug 2025US$1.0tUS$158.4b-US$20,947,422,497.0215.8x-48.4x6.4x
Wed, 02 Jul 2025US$927.2bUS$156.0b-US$23,839,320,142.0917.5x-38.9x5.9x
Fri, 30 May 2025US$914.8bUS$155.9b-US$23,981,521,247.8015.7x-38.1x5.9x
Sun, 27 Apr 2025US$783.3bUS$119.2b-US$31,074,126,492.8219.8x-25.2x6.6x
Tue, 25 Mar 2025US$827.0bUS$118.6b-US$36,869,226,191.9320.7x-22.4x7x
Thu, 20 Feb 2025US$842.4bUS$116.6b-US$36,830,915,932.5217.4x-22.9x7.2x
Sat, 18 Jan 2025US$943.3bUS$149.4b-US$26,286,132,923.6717.3x-35.9x6.3x
Mon, 16 Dec 2024US$991.8bUS$150.0b-US$26,493,336,471.9416.6x-37.4x6.6x
Wed, 13 Nov 2024US$1.1tUS$149.6b-US$27,274,668,753.1816.1x-40.4x7.4x
Fri, 11 Oct 2024US$885.7bUS$113.1b-US$35,992,841,232.3420.3x-24.6x7.8x
Sun, 08 Sep 2024US$873.8bUS$113.1b-US$35,668,533,175.3222.2x-24.5x7.7x
Tue, 06 Aug 2024US$1.2tUS$165.8b-US$32,345,907,600.2024.9x-37x7.2x
Thu, 04 Jul 2024US$1.1tUS$164.5b-US$27,946,912,225.8427.9x-40.1x6.8x
Sat, 01 Jun 2024US$1.1tUS$164.6b-US$26,677,227,566.3227.4x-41.6x6.7x
Mon, 29 Apr 2024US$1.1tUS$164.6b-US$27,372,800,636.0922.6x-39.1x6.5x
Wed, 27 Mar 2024US$1.2tUS$164.4b-US$23,792,606,116.0221.2x-48.8x7.1x
Fri, 23 Feb 2024US$1.2tUS$169.0b-US$20,212,652,991.5813.2x-57x6.8x
Sun, 21 Jan 2024US$1.4tUS$204.8b-US$22,506,538,466.0018.5x-63.3x7x
Tue, 19 Dec 2023US$1.4tUS$204.7b-US$22,117,247,361.0019.2x-61x6.6x
Thu, 16 Nov 2023US$1.2tUS$204.7b-US$22,143,559,902.0018.4x-55.1x6x
Sat, 14 Oct 2023US$1.3tUS$207.3b-US$13,141,713,262.0016.6x-96.4x6.1x
Mon, 11 Sep 2023US$1.3tUS$207.5b-US$12,633,744,533.0017.4x-101x6.1x
Wed, 09 Aug 2023US$1.3tUS$206.4b-US$12,500,248,802.0016.4x-101x6.1x
Fri, 07 Jul 2023US$1.1tUS$186.2b-US$16,056,868,924.0013.2x-69.5x6x
Sun, 04 Jun 2023US$1.1tUS$185.9b-US$16,014,255,509.0011.4x-71.1x6.1x
Price to Earnings Ratio

-71.1x


Total Market Cap: US$1.1tTotal Earnings: -US$16,014,255,509.00Total Revenue: US$185.9bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Biotech Industry Price to Earnings3Y Average -57.8x202420252026
Current Industry PE
  • Investors are optimistic on the American Biotechs industry, and appear confident in long term growth rates.
  • The 3-year average PS ratio of 6.9x is lower than the industry's current PS ratio of 7.6x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 2.9% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market1.27%
Healthcare0.96%
Biotech1.02%
Biotech1.02%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ABBV AbbVieUS$215.401.5%
+US$5.5b		17.6%PE105.9x
GILD Gilead SciencesUS$133.692.3%
+US$3.7b		23.3%PE18x
AMGN AmgenUS$336.061.4%
+US$2.4b		20.7%PE23.3x
VRTX Vertex PharmaceuticalsUS$437.221.6%
+US$1.7b		-1.8%PE25.6x
BIIB BiogenUS$196.974.9%
+US$1.4b		54.4%PE21.2x

Latest News

ABBV
US$215.40
AbbVie
7D
1.5%
1Y
17.6%
ASND
US$235.26
Ascendis Pharma
7D
-2.5%
1Y
n/a
Seeking Alpha • 11h

Ascendis Pharma: Rare Endocrine Compounder Entering Growth Phase (Initiating Buy)

Summary Ascendis Pharma is initiated with a buy rating, reflecting its transition to a durable, commercial-stage rare endocrine franchise. ASND's valuation premium is justified by high-quality revenue growth, multiple product launches, operating leverage, and reduced financing risk. Yorvipath and Yuviwel are driving robust pipeline momentum, with Yorvipath scaling rapidly in chronic hypoparathyroidism and Yuviwel poised for expansion in achondroplasia. The next 12–18 months are catalyst-rich, with regulatory, clinical, and commercial milestones supporting the self-funded growth strategy and platform expansion. Read the full article on Seeking Alpha
ALNY
US$295.63
Alnylam Pharmaceuticals
7D
-1.0%
1Y
3.5%
CGON
US$60.80
CG Oncology
7D
-6.1%
1Y
140.5%
BIIB
US$196.97
Biogen
7D
4.9%
1Y
54.4%
Narrative Update • May 26

BIIB: Tau Alzheimer’s Data And EPS Upside Will Drive Future Upside

Biogen's updated analyst price target has shifted from about $206 to $219, as analysts weigh mixed but encouraging tau program data, potential EPS upside, and a modestly higher assumed future P/E multiple. Analyst Commentary Recent research views on Biogen cluster around mixed tau data, potential earnings power, and how much of that is already reflected in the stock's valuation.
AMGN
US$336.06
Amgen
7D
1.4%
1Y
20.7%
ROIV
US$29.58
Roivant Sciences
7D
-8.7%
1Y
178.5%
REGN
US$627.74
Regeneron Pharmaceuticals
7D
-3.4%
1Y
6.1%
Narrative Update • May 26

REGN: Fair Outlook As LAG 3 Setback Reshapes Pipeline And Product Prospects

Analysts have trimmed their fair value estimate for Regeneron Pharmaceuticals to $641 from $730, reflecting lower assumed profit margins and a reduced future P/E multiple after the recent fianlimab LAG-3 trial setbacks and related cuts to price targets across the Street. Analyst Commentary Street research has turned more cautious on Regeneron following the failed Phase 3 LAG-3 melanoma trial for fianlimab, with a series of reduced price targets and several rating downgrades.
IMVT
US$33.41
Immunovant
7D
-6.0%
1Y
137.0%
Seeking Alpha • May 25

Immunovant: Upgraded To 'Buy' Because Of IMVT-1402's Broad Potential

Summary Immunovant's underlying bull case has now moved away from batoclimab and toward IMVT-1402. This newer asset has encouraging data for difficult-to-treat RA. By week 16, 72.7% of hard-to-treat RA patients had good responses with IMVT-1402. IMVT also has a solid balance sheet this time around. And management believes its runway is sufficient through their next readouts. IMVT-1402 is particularly promising because it could work across several indications. I think it could become a franchise asset, but future readouts still have to confirm that. Overall, I think IMVT is a viable speculative “Buy” at these levels, despite its inherent clinical trial risks. IMVT-1402’s potential as a broad FcRn platform makes it worth the risk. Read the full article on Seeking Alpha
BNTX
US$93.00
BioNTech
7D
2.9%
1Y
-4.6%
SMMT
US$17.36
Summit Therapeutics
7D
-3.0%
1Y
-33.3%
VRTX
US$437.22
Vertex Pharmaceuticals
7D
1.6%
1Y
-1.8%
ONC
US$300.01
BeOne Medicines
7D
-2.8%
1Y
24.8%
Narrative Update • May 23

ONC: Hematology Franchise And Upcoming Trial Readouts Will Support Future Upside

Analysts lifted the price target on BeOne Medicines by $3 to $411.51, as updated models reflect the recent FDA accelerated approval for sonrotoclax in relapse and refractory mantle cell lymphoma, along with ongoing combination trials and a higher assumed profit margin that more than offsets slightly lower projected revenue growth and a reduced future P/E multiple. Analyst Commentary Recent research on BeOne Medicines centers on how the first FDA accelerated approval for sonrotoclax and the outlook for Brukinsa affect valuation, growth expectations, and perceived execution risk.
RLAY
US$14.43
Relay Therapeutics
7D
10.8%
1Y
389.2%
GILD
US$133.69
Gilead Sciences
7D
2.3%
1Y
23.3%
PRAX
US$357.13
Praxis Precision Medicines
7D
6.4%
1Y
864.4%